-+ 0.00%
-+ 0.00%
-+ 0.00%

LILLY'S OLOMORASIB RECEIVES U.S. FDA'S BREAKTHROUGH THERAPY DESIGNATION FOR THE TREATMENT OF PREVIOUSLY TREATED KRAS G12C-MUTANT ADVANCED PANCREATIC CANCER

Reuters·08/03/2026 11:45:00

Please log in to view news